Xinxiang Key Laboratory of Pathogenic Biology, Department of Pathogenic Biology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China.
Institute of Medical Laboratory Animal Science, Chinese Academy of Medical Sciences & Comparative Medical Center, Peking Union Medical College, Beijing, China.
Animal Model Exp Med. 2022 Dec;5(6):513-531. doi: 10.1002/ame2.12233. Epub 2022 Jul 26.
Hypertension is an important global public health issue because of its high morbidity as well as the increased risk of other diseases. Recent studies have indicated that the development of hypertension is related to the dysbiosis of the gut microbiota in both animals and humans. In this review, we outline the interaction between gut microbiota and hypertension, including gut microbial changes in hypertension, the effect of microbial dysbiosis on blood pressure (BP), indicators of gut microbial dysbiosis in hypertension, and the microbial genera that affect BP at the taxonomic level. For example, increases in Lactobacillus, Roseburia, Coprococcus, Akkermansia, and Bifidobacterium are associated with reduced BP, while increases in Streptococcus, Blautia, and Prevotella are associated with elevated BP. Furthermore, we describe the potential mechanisms involved in the regulation between gut microbiota and hypertension. Finally, we summarize the commonly used treatments of hypertension that are based on gut microbes, including fecal microbiota transfer, probiotics and prebiotics, antibiotics, and dietary supplements. This review aims to find novel potential genera for improving hypertension and give a direction for future studies on gut microbiota in hypertension.
高血压是一个重要的全球公共卫生问题,因为它的发病率高,而且增加了其他疾病的风险。最近的研究表明,高血压的发展与动物和人类肠道微生物群落的失调有关。在这篇综述中,我们概述了肠道微生物群与高血压之间的相互作用,包括高血压患者肠道微生物群的变化、微生物失调对血压的影响、高血压患者肠道微生物失调的指标以及在分类学水平上影响血压的微生物属。例如,乳酸杆菌、Roseburia、Coprococcus、Akkermansia 和双歧杆菌的增加与血压降低有关,而链球菌、Blautia 和普雷沃氏菌的增加与血压升高有关。此外,我们还描述了肠道微生物群与高血压之间调节的潜在机制。最后,我们总结了基于肠道微生物群的高血压常用治疗方法,包括粪便微生物群移植、益生菌和益生元、抗生素和膳食补充剂。本综述旨在寻找改善高血压的潜在新属,并为高血压肠道微生物群的未来研究提供方向。